Keapstone Therapeutics Limited, a single-asset virtual biotech with an innovative disease-modifying therapeutic approach to motor neuron...

Parkinson’s UK is pleased to announce the release of the next tranche of funding to continue our collaboration with Selcia (part of...

Parkinson’s UK is pleased to announce the release of the next tranche of funding to US company Neurolixis to continue final pre-clinical...

We're pleased to announce that Keapstone Therapeutics, a spin-out company formed as part of the Parkinson's Virtual Biotech, now has it's...

KEAPSTONE THERAPEUTICS was created in February 2017 as a single-asset virtual biotech company, spun out of University of Sheffield with seed

A new collaboration in the efforts to find a new drug candidate to combat Parkinson’s has been announced in the UK today. The...